Amphetamine vs Dextroamphetamine for focus
Short answer: For focus, users rate them about the same: 85% report improvement with Amphetamine (428 reports) and 88% with Dextroamphetamine (48 reports).
Amphetamine has 258 meta-analyses and 521 randomized trials on PubMed; Dextroamphetamine has 48 and 119.
Based on 878 reports about Amphetamine and 121 about Dextroamphetamine. Not medical advice.
| Amphetamine Medication | Dextroamphetamine Medication | |
|---|---|---|
| Users say it helped | 35%helped606 reports · high confidence | 43%helped81 reports · medium confidence |
| Verdict | Mixed | Mixed |
| Research | AResearch: Strong | AResearch: Strong |
| Meta-analyses / RCTs | 258 / 521 | 48 / 119 |
| Mainly used for | ||
| Focus % reporting improvement | 85% (428) | 88% (48) |
| Energy % reporting improvement | 75% (146) | 84% (19) |
| Mood % reporting improvement | 48% (132) | 41% (17) |
| Anxiety % reporting improvement | 38% (56) | 38% (8) |
| Sleep % reporting improvement | 9% (35) | 25% (4) |
| Common side effects | tolerance, anxiety, insomnia, jitteriness | anxiety, tolerance, insomnia, withdrawal |
| Typical dose reported | Not listed | Not listed |
Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu
PLoS One, 2020 ↗“Unfortunately the only thing that's ever works for me was using adderall. I didn't feel hungry until 3 pm and it was perfect.”
Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu
PLoS One, 2020 ↗“Keeps me focused without the anxiety Adderall started giving me; it helps me relax even.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate